No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
LCTX250117C2500
- 0.05
- 0.000.00%
15min DelayClose Jan 10 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume106 Open Interest2.50Strike Price0.00Turnover796.88%IV339.66%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2149Delta0.4608Gamma11.60Leverage Ratio-0.0132Theta0.0000Rho2.49Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
Maxim Group Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $3
Maxim Group Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Cuts Target Price to $3
D. Boral Capital Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Cuts Target Price to $2
Lineage Cell Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Lineage Cell Therapeutics Inc : H.c. Wainwright Raises Target Price to $9 From $7
Is Lineage Cell Therapeutics (LCTX) the Best New Pick in Brad Gerstner's Portfolio?